Background Despite significant clinical improvements, there is evidence of persisting airway inflammation in people with cystic fibrosis (CF) established on elexacaftor/tezacaftor/ivacaftor (ETI) therapy. As CF is a multi-system disease, systemic immune profiles can reflect local inflammation within the lungs and other organs. Understanding systemic inflammation after ETI therapy may reveal important translational insights. This study aims to profile systemic inflammatory changes and relate these to the well-documented improvements observed with ETI therapy. Methods We conducted a single-centre longitudinal study with 57 CF subjects initiating ETI therapy. All participants were Phe508del homozygous or Phe508del/minimal function. Blood samples were collected pre-ETI and 3–12 months post-therapy initiation. Analyses included mass spectrometry-based proteomics, a multiplex immunoassay, and flow cytometry for peripheral immune cell counts and phenotype. Controls samples were provided by 29 age-matched healthy controls. Results Systemic inflammation reduced with ETI therapy; however, the immune profile remained distinct from healthy controls. ETI reduced neutrophil counts and was associated with a more mature, less inflammatory phenotype, as well as a shift towards an immune resolving state associated with increased CD206 expression. Cytokines known to influence neutrophil levels reduced with therapy. Despite ETI therapy, neutrophil and monocyte counts remained elevated compared with healthy controls. There was no obvious association between the ETI-related improvements in systemic inflammation and lung function. Conclusions Patients with CF showed evidence of persisting systemic inflammation despite ETI therapy, which may have long-term potentially adverse effects on respiratory and other organ systems.
Background: Parasomnias are abnormal behaviours in sleep. Disorders that can cause microarousals, such as obstructive sleep apnoea (OSA) and periodic limb movements in sleep (PLMS) are often considered to trigger parasomnias. However, the prevalence and impact of OSA, and its specific clinical phenotypes, such as REM-related OSA (ROSA) and positional OSA (POSA), as well as PLMS in parasomnias are not fully explored. Methods: We analysed the polysomnography reports of 155 patients who were referred to our tertiary service with symptoms of parasomnia. The prevalence of OSA, ROSA, POSA, and PLMS, as well as their severity indices were correlated with the prevalence of specific parasomnias using logistic regression. Results: The prevalence of OSA and PLMS was 48% and 23%, respectively. Whilst OSA and PLMS were inversely related to NREM parasomnias, PLMS was directly related to RBD (p < 0.05). Moreover, there was a significant inverse correlation between the severity of PLMS and the prevalence of NREM parasomnias (β = −0.12, p = 0.03) and a direct correlation with RBD (β = 0.02, p = 0.04). However, following adjustments for age, BMI, and gender, only the inverse relationships between OSA and sleep terrors as well as POSA and sleep-related eating disorder remained significant. Conclusions: The prevalence of OSA and PLMS is high among patients with parasomnia. Due to the exploratory nature of the study, conclusions on the associations need to be validated in interventional trials.
Novel diagnostic tools have been developed to aid diagnosis and reduce misdiagnosis. However, the accuracy of these tools depends on estimates of disease prevalence. This study aimed to determine the prevalence of rheumatological diseases in a real-world cohort of patients and assess the rate of misdiagnosis at first presentation and follow-up. Patients with symptoms of inflammatory arthritis were referred by primary care. Rheumatologists made initial diagnoses, initiated treatment and revised diagnoses during follow-up. Clinical data including diagnoses were extracted from electronic patient records. Over 2 years, 260 patients were seen. Most patients presented with peripheral joint symptoms (95%), and 23% had axial involvement. Psoriasis was present in 15%, inflammatory bowel disease in 4% and uveitis in 4%. Autoantibodies were positive for cyclic citrullinated peptide in 11% and rheumatoid factor in 12%. Seventeen per cent (n = 45) of patients were misdiagnosed, with 8% (n = 20) initially diagnosed with 1 of the 5 most common rheumatological conditions but later found to have a noninflammatory disorder. Conversely, 7% (n = 17) initially received a diagnosis of an ‘other rheumatological disease’ but later had their diagnoses revised to 1 of the 5 most common rheumatological conditions. Disease prevalence is context-specific, and prevalence estimates in the intended setting should be determined prior to implementation of novel diagnostic tools. In real-world cohorts, noninflammatory diseases like chronic pain syndromes were more prevalent than in observational studies and registries. Misdiagnosis occurs in about one-fifth of patients, highlighting the benefits of novel diagnostic tools for earlier, more accurate diagnosis.